ME-401 combined with rituximab-bendamustine for high-risk and rituximab with a 1:1 randomization to ME-401 for low-risk follicular lymphoma as primary treatment: a phase II study – NLG-FL5 (Follicular lymphoma and ME-401: FLAME)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501138-49-00

Acronym

NLG-FL5 FLAME

Enrollment

Registered

2022-10-14

Start date

Unknown

Completion date

2022-12-01

Last updated

2022-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Follicular Lymphoma

None listed

Sex/Gender

All

Age

18 Years to No maximum

Sweden

None listed

Source: EU CTIS · Data processed: Feb 4, 2026